BioCryst Pharma (BCRX) Receives $2.4M Contract Modification from NIAID for BCX4430 Efficacy Study
Tweet Send to a Friend
BioCryst Pharma (NASDAQ: BCRX) announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded a contract modification ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE